At market placement raises up to A$1.1 million

A further private placement to new strategic investors brings total raised in October to $1.6m, strengthens AdAlta’s ability to close cellular immunotherapy transactions, balance sheet

• AdAlta has received firm commitments to raise A$1.1 million from a group of sophisticated investors (subject to shareholder approval at the forthcoming AGM) via a private placement

• Placement brings total raised in October to up to $1.6 million

• Issue Price of 0.3c per share ($0.003) is equal to the closing price on 17 October

• Company will, subject to shareholder approval, issue Subscription Shares and Attaching Options on the same terms as the recent fully subscribed Entitlement Offer and $0.5 million placement

• Placement facilitated by Lead Manager, 62 Capital Pty Ltd

• Proceeds provide balance sheet flexibility, strengthening AdAlta’s position as it advances “East to West” cellular immunotherapy transactions and other strategic options

• AGM to now be held 26 November 2025